Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs placebo in ankylosing spondylitis (NSAID failure, TNF-naïve)
2009-017443-34Phase 2Terminated
- Sponsor
- Roche
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Tocilizumab with Placebo (2 arms). Primary endpoints: ASAS 20 response at week 12 (Part 1) and ASAS 20 response at week 12 (Part 2). Started Aug 2010; status: terminated.
02
Drugs
tocilizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2009-017443-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017443-34.